Immunization

As vaccine hesitancy grows, fewer children are receiving routine childhood vaccines.

A selection of the latest COVID-19 vaccine research out of IDWeek 2022.

What does the uptake look like for one of the most common vaccines given during pregnancy—and what does this mean for the future?

Adults who receive influenza and pneumococcal vaccines may be more likely to receive COVID-19 vaccines and boosters.

Pharmacists can play a key role in helping to improve backsliding vaccination rates.

Final thoughts are provided as the panelists consider opportunities in the field of influenza vaccination.

The panel provides opinions on the incorporation of vaccine awareness and administration from public and state levels.

Distinctions between vaccine types are explored, as well as considerations such as egg-based allergies.

Vaccination discussion continues with a focus on navigating patient concerns and potential adverse effects to vaccine administration.

Infants of fully vaccinated mothers had fewer cases of hospitalization from COVID-19 than those unvaccinated.

William J. Muller, MD, PhD, discusses COVID-19 vaccinations for children of all ages and describes what is on the horizon for RSV.

When it comes to the COVID-19 vaccine, independent pharmacies are being set up to fail by federal health partners.

This National Immunization Awareness Month, prepare your pharmacy to offer important vaccines.

Pfizer-BioNTech hopes booster can be available for use this fall.

Mitchel Rothholz, RPh, MBA, leads panelists in a conversation regarding strategies to manage increased pharmacist workload in anticipation of the coming flu season.

A panel of experts open a discussion surrounding influenza vaccines amid patient vaccine hesitancy.

Domestic production to begin at Michigan-based pharmaceutical maker.

The FDA has granted Emergency Use Authorization EUA of the Jynneos vaccine for pediatric patients <18 years who are at high risk of monkeypox infection.

The latest guidance for when to administer the COVID-19 vaccine to patients aged 6 months and older.

Adults aged 18 and older are eligible to receive the vaccine.

Purchase follows FDA recommendation to include Omicron component in boosters.

The preferential recommendation is built on research and real-world data

The FDA approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.

The FDA announced the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.

The program administered 60 vaccines to patients referred by their primary care physicians.